Introduction
Before treatment with levodopa became available anticholinergic drugs were the mainstay of drug treatment in Parkinsonism and produced an estimated 20o0 improvement (Yahr et al., 1969) , mainly in the features of rigidity and tremor; hypersalivation was also considerably improved in many cases. The advent of levodopa with its beneficial effects of varying degrees in all types and all aspects of Parkinsonism has raised the important question of whether anticholinergic drugs should be continued in patients receiving levodopa therapy or whether they should be given in addition when levodopa is used as the primary treatment. It is well known that rapid deterioration in the Parkinsonian state may occur when anticholinergic drugs, used as the only treatment, are withdrawn. It seemed important therefore to determine -whether continued anticholinergic therapy was necessary in addition to levodopa therapy, whether any synergism existed between the two forms of treatment, and to delineate those clinical features, if any, which responded preferentially to anticholinergic drugs.
A study was therefore designed in order to analyse the the effects of withdrawal of anticholinergic drugs in a group of patients receiving a stable dosage of levodopa. In view of the likelihood that sudden withdrawal would be followed by non-specific side effects patients were allocated to two groups in one of which such withdrawal was sudden and in the other gradual.
Patients and Methods Thirty-six patients with paralysis agitans (idiopathic Parkinsonism) (20 male, 16 female) who had been receiving a constant amount of anticholinergic therapy for a number of years, and who had responded to levodopa which they had been taking in stable dosage for two months or more, were admitted to the trial. The duration of disease in these patients varied from 3 to 28 years.
Most of the patients were receiving benzhexol (Artane) or orphenadrine hydrochloride (Disipal) either alone or in combination with benztropine (Cogentin) and had been taking these drugs for at least five years. Patients were allocated to the gradual (group 1) or sudden (group 2) withdrawal groups in such a way that the doses and combinations of anticholinergic drugs were matched as closely as possible in each group (Table TABLE I I); the groups were also matched so as to include equal numbers of patients who had undergone previous stereotaxic surgery. There were 18 patients in each group. In group 1 anticholinergic drugs were reduced by one-quarter of the total dose per week, so that at the four-week stage these drugs had been discontinued; and in group 2 the drugs were stopped abruptly. In each group clinical assessments were carried out immediately before the trial and at two-weekly intervals thereafter for eight weeks. The patients were assessed clinically by one of two of us (R.C.H. and J.G.P.) by the methods described in a previous study (Hughes et al., 1971 similar effects. It is worthy of note, however, that two patients (Cases 24 and 28) who noted gross deterioration on withdrawal were also receiving benztropine; the deterioration in Case 28 was completely reversed by restarting benztropine alone. These findings are in accordance with the accepted fact that benztropine is the most potent anticholinergic drug in general usage. Two patients felt they were improved on withdrawal, particularly with regard to speech, and in one of these walking was said to be improved; these impressions could not be confirmed clinically.
Of the 17 patients in group 1 five said they felt no change, two felt better, and 10 felt worse. The number of patients noting deterioration is statistically significant (1P <0 05). Of the 17 patients in group 2, two said they felt no change, none felt better, and 15 felt worse. This again is significant (P <0-01).
STATISTICAL ANALYSIS
The assessment of the four main clinical features-namely, bradykinesia, rigidity, tremor, and gait-together with the results of the four timed tests previously described (Hughes et al., 1971) were analysed. The change in score from prewithdrawal to each two-weekly assessment was the measure of improvement or otherwise in the patient. Groups 1 and 2 were considered separately by these within-patient comparisons and the mean change for the group at each time interval was tested against zero (Tables III-VI).
In both groups 1 and 2 the numbers of patients able to tolerate anticholinergic withdrawal decreased progressively at each assessment interval. This was particularly so in group 2 where only four patients were able to tolerate withdrawal to the eight-week stage compared with 12 in group 1. One patient did not attend for assessment at the eight-week stage.
In group 1 there was on average a non-significant deterioration in bradykinesia, rigidity, and tremor and a non-significant improvement in gait when assessments of these features were compared with those obtained before withdrawal. Of the timed tests, repeated handgrips and rising from a chair showed on average a non-significant deterioration and restacking books a non-significant improvement. Walking a set distance, however, showed on average a significant improvement at two weeks which was maintained at the later assessments (see Table III ). No reason other than anticholinergic withdrawal could be found to account for this improvement, but it should be noted that this result is in agreement with the non-significant gait improvement noted at each assessment period. It is possible that continuing improvement due to levodopa was responsible for this finding. In group 2 patients there was on average a non-significant deterioration in all four main clinical features at two and four weeks with the exception of rigidity, which was significantly worse at two weeks (Table IV) . All timed tests showed a deterioration at the two-week stage which was significant for rising from a chair (P <0 05) (Table V) and highly significant for repeated handgrips (P <0 001) (Table VI) . At the later stages when patients unable to tolerate withdrawal had returned to taking anticholinergic drugs, and hence could not be included in the further analysis, the changes were not significant.
When groups 1 and 2 were compared with respect to clinical features and timed tests there was a significant difference between changes noted in gait, walking a set distance, and repeated handgrips, the changes being more favourable for group 1 patients. The differences, however, were significant only at the two-week stage when there was a maximum difference between the amount of anticholinergic drugs being taken by the two groups (Tables VII-IX (Siegel, 1956) (Table VIII) . When the numbers of patients returning to anticholinergic therapy in group 2 were compared with those in group 1 the difference was significant at each trial interval (Table X) . (Hughes et al., 1971) eight-week stage were plotted against levodopa dosage (Fig. 2 ) the association was significant at the lo level. These results suggest that patients tolerating lower doses of levodopa may benefit even more than those receiving a higher dosage from the addition of anticholinergic drugs. Previous stereotaxic surgery, either bilateral or unilateral, did not appear to influence the need to restore anticholinergic therapy, nor did the duration of the Parkinsonian syndrome.
Discussion
The fact that anticholinergic drugs could be withdrawn in only 11 of the 34 patients on stable levodopa therapy and the spectrum of symptoms which emerged during withdrawal suggest that there is a synergism between levodopa and anticholinergic drugs and that some features of Parkinsonism, especially hypersalivation, respond equally well or even preferentially to anticholinergic drugs. The increased slowness noted by 20 patients after withdrawal is surprising, since it is bradykinesia and akinesia that respond best to levodopa. However, gross deterioration in this feature was noted by only four patients. We were able to verify this clinically in one patient whose writing also showed a pronounced deterioration (Fig. 3) . The other three
The average daily dose of levodopa for the patients in the two groups was equal at 2-7 g, and in group 2 (sudden withdrawal) the dosage of levodopa being given in individual cases bore no relationship to the degree of deterioration. In group 1, however, patients who noticed no change or showed improvement on withdrawal were taking an average dose of 3-1 g compared with 2-2 g in those patients who resumed anticholinergic drugs because of deterioration. This finding is supported by a significant association between the dosage of levodopa and tbe degree and direction of clinical change at the eight-week stage of slow withdrawal. The scores of the four main clinical features were combined and changes at eight weeks were plotted against the dosage of levodopa (r with 9 D.F. = -0-634 P <005) (Fig. 1) . When changes in the combined timed tests at the had recommenced anticholinergic therapy, because of gross deterioration, before they could be reassessed. The fact that only three patients were able to tolerate withdrawal beyond the eight-week stage in group 2 compared with eight in group 1 suggests that rapid withdrawal was a factor in determining these numbers, particulatly since the four patients who exhibited gross deterioration on withdrawal were all in group 2. Nevertheless, even in group 1 nine patients had to return to anticholinergic therapy (which in one patient had consisted of only 2 mg of benzhexol a day) at or before the end of the trial and a further three have recommenced such treatment since the termination of the trial.
Information in the literature regarding the combined use of levodopa and anticholinergic drugs is relatively sparse, though a number of authors have commented that anticholinergic drugs were not discontinued when levodopa therapy was initiated. A possible reason why levodopa and anticholinergic drugs act synergistically is that the dopamine formed from levodopa may be inactivated by the neuronal membrane uptake system which in turn is inhibited by anticholinergic drugs as suggested by Coyle and Synder (1969) . The prevention of dopamine inactivation by anticholinergic drugs gains some support from the following clinical observations noted on withdrawal of such treatment: (1) the complaints of increased slowness in 590/ of patients and of increased tremor in 44%, (2) an apparent reduction in the duration of the effect of individual doses of levodopa in three patients, and (3) decrease in levodopainduced involuntary movements in five patients. All of these effects were reversed by the resumption of anticholinergic drugs. 491 An alternative and perhaps more likely explanation for the synergism of levodopa and anticholinergic drugs is that levodopa therapy, while producing repletion of striatal dopamine, still cannot completely redress the dopaminergic/ cholinergic imbalance and that a central anticholinergic effect is still required to produce a maximum therapeutic effect.
Introduction
The space-time clustering of Burkitt's lymphoma cases which has been demonstrated in the West Nile District of Uganda (Williams et al., 1969) suggests that an infective agent is involved in the development of the tumour. The West Nile clustering pointed to a few months and 10 to 20 kilometres as the pertinent units of time and distance between clustered cases.
Chronic intense malaria infection seems to play a crucial background role in the genesis of Burkitt's lymphoma (Burkitt, 1969) ; and it is well established that all patients with Burkitt's lymphoma have antibodies to Epstein-Barr virus, the majority at high titres (Henle et al., 1969) . A combination of infection with malaria and Epstein-Barr virus is the currently most favoured hypothesis concerning the cause of the disease. The principal epidemiological evidence for a role for malaria is the close geographic coincidence of falciparum malaria and Burkitt's lymphoma (Kafuko and Burkitt, 1970) . Experimental support is provided by the finding that mice infected with a murine plasmodium, P. berghei yoelii, are more susceptible to lymphoma development when challenged with Moloney leukaemogenic virus (Wedderburn, 1970 (Churchill and Biggs, 1967) , frog kidney carcinoma (Mizell et al., 1969) , and malignant lymphoreticular proliferation in primates (Melendez et al., 1969) .
However, to account for Burkitt's lymphoma space-time clustering on the basis of these two highly prevalent endemic infections is very difficult.
Malaria is hyperendemic and holoendemic in West Nile (Kafuko et al., 1969) and Epstein-Barr virus infection is so common that 85 o or more of children have detectable antibodies to it by the age of 3 years (Henle et al., 1969; East African Virus Research Institute, 1970) . Moreover, the interaction between Epstein-Barr virus and malaria would be expected to be maximal at very young ages, when malaria is producing its greatest stress. The incidence of Burkitt's lymphoma is, however, at a peak round age 7, with a wide age range.
With our present knowledge of malaria and Epstein-Barr virus infection, and requiring a latent period of five years with a lot of variability, the observed space-time clustering of tumour cases would not be expected on the basis of any interaction between the two agents alone. Though it may be possible to build a hypothetical model for clustering dependent on some postulated peculiarity-for example, an unusual route of entry for Epstein-Barr virus at a critical time-there is no evidence at present to support such a model. Thus the clustering evidence stands as a challenge to this hypothesis.
However, the space-time clustering which continues to be observed in West Nile (Kafuko et al., 1971) 
